Form 8-K - Current report:
SEC Accession No. 0001564590-22-010864
Filing Date
2022-03-17
Accepted
2022-03-17 16:07:18
Documents
14
Period of Report
2022-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-8k_20220317.htm   iXBRL 8-K 42166
2 EX-99.1 trvi-ex991_6.htm EX-99.1 142977
3 GRAPHIC g3zsz0wdgmtp000001.jpg GRAPHIC 29443
  Complete submission text file 0001564590-22-010864.txt   369318

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA trvi-20220317.xsd EX-101.SCH 5721
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20220317_lab.xml EX-101.LAB 20073
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20220317_pre.xml EX-101.PRE 11961
8 EXTRACTED XBRL INSTANCE DOCUMENT trvi-8k_20220317_htm.xml XML 3685
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 22748555
SIC: 2834 Pharmaceutical Preparations